Werewolf Therapeutics, Inc. Insider Trading
HOWL
Insiders sold $2.15M and bought nothing on the open market.
All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jan 2023.
Get an email when HOWL's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jul 6 – 7 | Luke Evnin Director | Sold10b5-1 plan 2 parts | 143,199 | $0.31 average | 45K | 100% | Form 4 |
| Jun 29 | Luke Evnin Director | Sold10b5-1 plan | 157,084 | $0.30 | 47K | 52% | Form 4 |
| Jun 17 | RA Capital Management, L.p. Large holder | SoldNo plan 2 parts | 416,911 | $0.35 average | 146K | 58% | Form 4 |
| Jun 12 – 16 | RA Capital Management, L.p. Large holder | SoldNo plan 6 parts | 448,836 | $0.39 average | 174K | 58% | Form 4 |
| Jun 9 – 11 | Peter Kolchinsky Large holder | SoldNo plan 6 parts | 678,226 | $0.37 average | 254K | 65% | Form 4 |
| Jun 9 | Luke Evnin Director | Sold10b5-1 plan | 76,928 | $0.37 | 28K | 20% | Form 4 |
| Jun 4 – 8 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 105,565 | $0.41 average | 43K | 22% | Form 4 |
| Jun 1 – 3 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 139,803 | $0.46 average | 64K | 22% | Form 4 |
| May 27 – 29 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 141,106 | $0.47 average | 66K | 18% | Form 4 |
| May 21 – 26 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 191,762 | $0.45 average | 87K | 20% | Form 4 |
| May 18 – 20 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 171,049 | $0.45 average | 76K | 15% | Form 4 |
| May 13 | Luke Evnin Director | Sold10b5-1 plan | 44,679 | $0.54 | 24K | 3.8% | Form 4 |
| May 8 – 12 | RA Capital Management, L.p. Large holder | SoldNo plan 6 parts | 565,167 | $0.69 average | 391K | 58% | Form 4 |
| May 8 – 12 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 407,574 | $0.69 average | 280K | 26% | Form 4 |
| May 5 – 7 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 100,581 | $0.64 average | 64K | 6.0% | Form 4 |
| Apr 30 – May 4 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 274,619 | $0.72 average | 198K | 14% | Form 4 |
| Apr 27 – 29 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 205,911 | $0.75 average | 155K | 9.5% | Form 4 |
| Jan 16 | Luke Evnin Director | Sold10b5-1 plan | 38,782 | $0.54 | 21K | 1.8% | Form 4 |
| Jan 13 – 15 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 111,227 | $0.56 average | 62K | 4.8% | Form 4 |
| Jan 8 – 12 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 91,374 | $0.59 average | 54K | 3.8% | Form 4 |
| Jan 5 – 7 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 71,054 | $0.65 average | 46K | 2.9% | Form 4 |
| Dec 30, 2025 – Jan 2 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 78,377 | $0.62 average | 48K | 3.1% | Form 4 |
| Dec 22, 2025 – Dec 29, 2025 | Luke Evnin Director | Sold10b5-1 plan 5 parts | 291,283 | $0.64 average | 185K | 10% | Form 4 |
| Dec 15, 2025 – Dec 17, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 48,171 | $1.08 average | 52K | 1.7% | Form 4 |
| Dec 10, 2025 – Dec 12, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 82,971 | $1.07 average | 89K | 2.8% | Form 4 |
| Dec 5, 2025 – Dec 9, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 95,179 | $1.00 average | 95K | 3.1% | Form 4 |
| Dec 2, 2025 – Dec 4, 2025 | MPM Bioventures 2014 (b), L.p. Large holder | Sold10b5-1 plan 3 parts | 199,732 | $0.92 average | 183K | 4.0% | Form 4 |
| Dec 2, 2025 – Dec 4, 2025 | MPM Bioimpact LLC Large holder | Sold10b5-1 plan 3 parts | 199,732 | $0.92 average | 183K | 4.0% | Form 4 |
| Dec 2, 2025 – Dec 4, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 128,185 | $0.92 average | 118K | 4.0% | Form 4 |
| Nov 26, 2025 – Dec 1, 2025 | MPM Asset Management Investors Bv2014 LLC Large holder | Sold10b5-1 plan 3 parts | 141,927 | $0.96 average | 137K | 2.8% | Form 4 |
| Nov 26, 2025 – Dec 1, 2025 | UBS Oncology Impact Fund L.p. Large holder | Sold10b5-1 plan 3 parts | 141,927 | $0.96 average | 137K | 2.8% | Form 4 |
| Nov 26, 2025 – Dec 1, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 91,088 | $0.96 average | 88K | 2.8% | Form 4 |
| Nov 21, 2025 – Nov 25, 2025 | MPM Bioventures 2014 GP LLC Large holder | Sold10b5-1 plan 3 parts | 195,666 | $0.92 average | 180K | 3.7% | Form 4 |
| Nov 21, 2025 – Nov 25, 2025 | MPM Oncology Innovations Fund GP LLC Large holder | Sold10b5-1 plan 3 parts | 195,666 | $0.92 average | 180K | 3.7% | Form 4 |
| Nov 21, 2025 – Nov 25, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 125,576 | $0.92 average | 115K | 3.7% | Form 4 |
| Nov 18, 2025 – Nov 20, 2025 | MPM Bioventures 2014 LLC Large holder | Sold10b5-1 plan 3 parts | 160,103 | $0.92 average | 148K | 2.9% | Form 4 |
| Nov 18, 2025 – Nov 20, 2025 | MPM Oncology Innovations Fund GP LLC Large holder | Sold10b5-1 plan 3 parts | 160,103 | $0.92 average | 148K | 2.9% | Form 4 |
| Nov 18, 2025 – Nov 20, 2025 | Luke Evnin Director | Sold10b5-1 plan 3 parts | 102,753 | $0.92 average | 95K | 2.9% | Form 4 |
| Nov 13, 2025 – Nov 17, 2025 | MPM Bioventures 2014 LLC Large holder | Sold10b5-1 plan 3 parts | 209,652 | $0.96 average | 201K | 3.7% | Form 4 |
| Nov 13, 2025 – Nov 17, 2025 | MPM Oncology Innovations Fund GP LLC Large holder | Sold10b5-1 plan 3 parts | 209,652 | $0.96 average | 201K | 3.7% | Form 4 |
- Jul 6 – 710b5-1 planLuke EvninDirector · sold 143,199 at avg $0.3145K100% of stake
- Jun 2910b5-1 planLuke EvninDirector · sold 157,084 at $0.3047K52% of stake
- Jun 17No planRA Capital Management, L.p.Large holder · sold 416,911 at avg $0.35146K58% of stake
- Jun 12 – 16No planRA Capital Management, L.p.Large holder · sold 448,836 at avg $0.39174K58% of stake
- Jun 9 – 11No planPeter KolchinskyLarge holder · sold 678,226 at avg $0.37254K65% of stake
- Jun 910b5-1 planLuke EvninDirector · sold 76,928 at $0.3728K20% of stake
- Jun 4 – 810b5-1 planLuke EvninDirector · sold 105,565 at avg $0.4143K22% of stake
- Jun 1 – 310b5-1 planLuke EvninDirector · sold 139,803 at avg $0.4664K22% of stake
- May 27 – 2910b5-1 planLuke EvninDirector · sold 141,106 at avg $0.4766K18% of stake
- May 21 – 2610b5-1 planLuke EvninDirector · sold 191,762 at avg $0.4587K20% of stake
- May 18 – 2010b5-1 planLuke EvninDirector · sold 171,049 at avg $0.4576K15% of stake
- May 1310b5-1 planLuke EvninDirector · sold 44,679 at $0.5424K3.8% of stake
- May 8 – 12No planRA Capital Management, L.p.Large holder · sold 565,167 at avg $0.69391K58% of stake
- May 8 – 1210b5-1 planLuke EvninDirector · sold 407,574 at avg $0.69280K26% of stake
- May 5 – 710b5-1 planLuke EvninDirector · sold 100,581 at avg $0.6464K6.0% of stake
- Apr 30 – May 410b5-1 planLuke EvninDirector · sold 274,619 at avg $0.72198K14% of stake
- Apr 27 – 2910b5-1 planLuke EvninDirector · sold 205,911 at avg $0.75155K9.5% of stake
- Jan 1610b5-1 planLuke EvninDirector · sold 38,782 at $0.5421K1.8% of stake
- Jan 13 – 1510b5-1 planLuke EvninDirector · sold 111,227 at avg $0.5662K4.8% of stake
- Jan 8 – 1210b5-1 planLuke EvninDirector · sold 91,374 at avg $0.5954K3.8% of stake
- Jan 5 – 710b5-1 planLuke EvninDirector · sold 71,054 at avg $0.6546K2.9% of stake
- Dec 30, 2025 – Jan 210b5-1 planLuke EvninDirector · sold 78,377 at avg $0.6248K3.1% of stake
- Dec 22, 2025 – Dec 29, 202510b5-1 planLuke EvninDirector · sold 291,283 at avg $0.64185K10% of stake
- Dec 15, 2025 – Dec 17, 202510b5-1 planLuke EvninDirector · sold 48,171 at avg $1.0852K1.7% of stake
- Dec 10, 2025 – Dec 12, 202510b5-1 planLuke EvninDirector · sold 82,971 at avg $1.0789K2.8% of stake
- Dec 5, 2025 – Dec 9, 202510b5-1 planLuke EvninDirector · sold 95,179 at avg $1.0095K3.1% of stake
- Dec 2, 2025 – Dec 4, 202510b5-1 planMPM Bioventures 2014 (b), L.p.Large holder · sold 199,732 at avg $0.92183K4.0% of stake
- Dec 2, 2025 – Dec 4, 202510b5-1 planMPM Bioimpact LLCLarge holder · sold 199,732 at avg $0.92183K4.0% of stake
- Dec 2, 2025 – Dec 4, 202510b5-1 planLuke EvninDirector · sold 128,185 at avg $0.92118K4.0% of stake
- Nov 26, 2025 – Dec 1, 202510b5-1 planMPM Asset Management Investors Bv2014 LLCLarge holder · sold 141,927 at avg $0.96137K2.8% of stake
- Nov 26, 2025 – Dec 1, 202510b5-1 planUBS Oncology Impact Fund L.p.Large holder · sold 141,927 at avg $0.96137K2.8% of stake
- Nov 26, 2025 – Dec 1, 202510b5-1 planLuke EvninDirector · sold 91,088 at avg $0.9688K2.8% of stake
- Nov 21, 2025 – Nov 25, 202510b5-1 planMPM Bioventures 2014 GP LLCLarge holder · sold 195,666 at avg $0.92180K3.7% of stake
- Nov 21, 2025 – Nov 25, 202510b5-1 planMPM Oncology Innovations Fund GP LLCLarge holder · sold 195,666 at avg $0.92180K3.7% of stake
- Nov 21, 2025 – Nov 25, 202510b5-1 planLuke EvninDirector · sold 125,576 at avg $0.92115K3.7% of stake
- Nov 18, 2025 – Nov 20, 202510b5-1 planMPM Bioventures 2014 LLCLarge holder · sold 160,103 at avg $0.92148K2.9% of stake
- Nov 18, 2025 – Nov 20, 202510b5-1 planMPM Oncology Innovations Fund GP LLCLarge holder · sold 160,103 at avg $0.92148K2.9% of stake
- Nov 18, 2025 – Nov 20, 202510b5-1 planLuke EvninDirector · sold 102,753 at avg $0.9295K2.9% of stake
- Nov 13, 2025 – Nov 17, 202510b5-1 planMPM Bioventures 2014 LLCLarge holder · sold 209,652 at avg $0.96201K3.7% of stake
- Nov 13, 2025 – Nov 17, 202510b5-1 planMPM Oncology Innovations Fund GP LLCLarge holder · sold 209,652 at avg $0.96201K3.7% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with HOWL
Spot a number that looks wrong? Check it in HOWL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HOWL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.